Esketamine will be marketed by Big Pharma as Spravato. So, what’s all the hype?

On February 12, 2019 the FDA advisory committee recommended approval of Spravato (esketamine) for adults with treatment resistant depression. Hallelujah! The first new therapy in 30 years for patients suffering from this affliction, or is it?